1. Scrip
  2. >>Advanced Therapies
  3. >>Cell Therapies

BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT

 
• By Joseph Haas and Sue Sutter

News and views from day one of the BIO International Convention: Merck reaffirms commitment to antibiotic space the same day Zerbaxa picks up a new indication; BIO survey finds out-licensing cash for emerging firms more than doubled in 2018; US FDA regenerative medicine advanced therapy designations now outnumber breakthrough designations for cell/gene therapies.

Bio 2019 Notebook for Scrip
Merck & Co. exec outlines one proposed "pull incentive" for antibiotic research called the Market Entry Reward. • Source: Shutterstock

On the same day that Merck & Co. Inc.'s Zerbaxa (ceftolozane/tazobactam) obtained a supplemental approval from the US FDA for hospital- and ventilator acquired pneumonia (HABP/VABP), the big pharma reaffirmed its commitment to the antibiotic space at the Biotechnology Innovation Organization’s annual convention in Philadelphia.

During a 3 June session on reimbursement reform for novel antibiotics in the US, Jenelle Krishnamoorthy, Merck & Co

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell Therapies

More from Advanced Therapies